Getting it Right (and Wrong) With Leveraged Biotech ETFs
In what looks like a sequel to March 2014, high-flying biotechnology stocks and exchange traded funds are retreating amid talk of frothy valuations and a biotech bubble.At least temporarily, Friday March 20 marked the top for several of the largest biotech ETFs. That is when big-name ETFs, such as the iShares Nasdaq Biotechnology ETF (IBB) , the largest biotech ETF, […]
